tion called the ‘‘common Hispanic mutation’’, has 
passed through 17 or more generations of American 
descendants from the original Spanish settlers of the 
Southwest in the 1590s. New Mexico has the highest 
population density of CCM in the world; Texas, Ari-
zona, and Colorado also have high rates of CCM due 
to the common Hispanic mutation. 
SEC. 3. EXPANSION AND COORDINATION OF ACTIVITIES OF 
NATIONAL INSTITUTES OF HEALTH WITH RE-
SPECT 
TO 
CEREBRAL 
CAVERNOUS 
MAL-
FORMATIONS RESEARCH. 
Part B of title IV of the Public Health Service Act 
(42 U.S.C. 284 et seq.) is amended by adding at the end 
the following: 
‘‘SEC. 409K. CEREBRAL CAVERNOUS MALFORMATIONS RE-
SEARCH ACTIVITIES. 
‘‘(a) EXPANSION
AND COORDINATION
OF ACTIVI-
TIES.—The Director of NIH, in coordination with the di-
rectors of the National Institute of Neurological Disorders 
and 
Stroke, 
the 
National 
Center 
for 
Advancing 
Translational Sciences, the National Heart, Lung, and 
Blood Institute, and other national research institutes, as 
appropriate, for the purpose of conducting research and 
related activities concerning cerebral cavernous malforma-
tions (referred to in this section as ‘CCM’)— 
VerDate Sep 11 2014 
02:51 May 28, 2015
Jkt 049200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H2480.IH
H2480
emcdonald on DSK67QTVN1PROD with BILLS
‘‘(1) shall strengthen and coordinate efforts of 
the National Institutes of Health; and 
‘‘(2) may award grants and cooperative agree-
ments to public or nonprofit private entities (includ-
ing State health departments, political subdivisions 
of States, universities, and other medical or edu-
cational entities). 
‘‘(b) ACTIVITIES.—The research and related activi-
ties described in subsection (a) shall include the following: 
‘‘(1) BASIC, TRANSLATIONAL, AND
CLINICAL 
RESEARCH.—The Director of NIH shall conduct or 
support, through funding opportunity announce-
ments, grants, or cooperative agreements, basic, clin-
ical, and translational research on CCM, including 
research on— 
‘‘(A) proteomic, pharmacological, and cell 
biological analysis of CCM molecules; 
‘‘(B) continued development and expansion 
of novel animal models for preclinical research 
relating to CCM; 
‘‘(C) early detection, diagnosis, and treat-
ment of CCM; 
‘‘(D) biological mechanisms for lesion gen-
esis, development, and maturation; 
VerDate Sep 11 2014 
02:51 May 28, 2015
Jkt 049200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H2480.IH
H2480
emcdonald on DSK67QTVN1PROD with BILLS
‘‘(E) biological mechanisms for lesion 
bleeding and symptomology; 
‘‘(F) novel biomedical and pharmacological 
interventions designed to inhibit new lesion de-
velopment, lesion growth, and lesion bleeding; 
‘‘(G) pre-clinical and clinical research re-
lated to repurposing currently approved drugs 
for treatment of CCM; 
‘‘(H) contributions of genetic variation to 
clinical presentation as targets for therapy; 
‘‘(I) identification and development of bio-
markers to measure phenotypic variation; 
‘‘(J) research related to improving the 
quality of life for individuals with CCM and 
their families; and 
‘‘(K) clinical training programs aimed at 
increasing the number of scientists and clini-
cians who are trained to treat patients and 
carry out the research described in this para-
graph. 
‘‘(2) FACILITATION OF RESEARCH RESOURCES; 
CLINICAL TRIAL PREPAREDNESS.— 
‘‘(A) IN GENERAL.—The Director of NIH 
shall award grants and contracts to public or 
nonprofit private entities to fund all or part of 
VerDate Sep 11 2014 
02:51 May 28, 2015
Jkt 049200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H2480.IH
H2480
emcdonald on DSK67QTVN1PROD with BILLS
the cost of planning, establishing, and providing 
basic operating support for a network of CCM 
Clinical Research Centers, including Coordi-
nating and Participating centers regarding re-
search on various forms of CCM. 
‘‘(B) CLINICAL AND RESEARCH COORDINA-
TION CENTERS.— 
‘‘(i) IN
GENERAL.—The Director of 
NIH shall identify and support the devel-
opment of 3 geographically distributed na-
tional clinical and research coordinating 
centers with unique clinical expertise and 
the potential for coordinating multi-site 
clinical drug trials with respect to CCM. 
‘‘(ii) DUTIES.—The coordinating cen-
ters identified under clause (i) shall pro-
vide a model for the participation centers 
described in paragraph (3), facilitate med-
ical research to develop a cure for CCM, 
and enhance the medical care of individ-
uals with CCM nationwide, including by— 
‘‘(I) maintaining an institutional 
infrastructure capable of hosting clin-
ical trials and facilitating translational 
VerDate Sep 11 2014 
02:51 May 28, 2015
Jkt 049200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H2480.IH
H2480
emcdonald on DSK67QTVN1PROD with BILLS
research projects and collaborations 
for clinical trials; 
‘‘(II) implementing the programs 
dedicated to patient education, patient 
outreach, and awareness developed by 
the Cerebral Cavernous Malformations 
Consortium 
under 
subsection 
(c)(3)(B); 
‘‘(III) developing the capacity to 
establish and maintain communication 
with other major CCM research and 
care institutions internationally for in-
formation sharing and coordination of 
research activities; 
‘‘(IV) demonstrating clinical ex-
pertise in the management of CCM 
and appointing a director and support 
staff, including a trainee and patient 
representative, for CCM research pro-
gramming; 
‘‘(V) treating a sufficient number 
of eligible patients for participation 
with particular focus on unique sub-
populations, such as patients with the 
common Hispanic mutation, Ash-
VerDate Sep 11 2014 
19:34 May 28, 2015
Jkt 049200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H2480.IH
H2480
emcdonald on DSK67QTVN1PROD with BILLS
kenazi Jewish mutation, or CCM3 
gene mutation carriers; and 
‘‘(VI) maintaining a telehealth 
infrastructure to support and provide 
clinical consultation for remote and 
underserved communities. 
‘‘(3) PARTICIPATION CENTERS.— 
‘‘(A) IN GENERAL.—The Director of NIH 
shall identify and support the development of 6 
to 10 clinical and research participation centers 
to facilitate medical research to develop a cure 
for CCM and enhance the medical care of indi-
viduals with CCM, in partnership with the co-
ordinating centers under paragraph (2) and 
other national and international entities, as ap-
propriate. 
‘‘(B) ELIGIBILITY.—To qualify for selec-
tion as a participation center under subpara-
graph (A), an entity shall— 
‘‘(i) at the time of selection— 
‘‘(I) be affiliated with an estab-
lished research network of the Na-
tional Institutes of Health; and 
VerDate Sep 11 2014 
02:51 May 28, 2015
Jkt 049200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H2480.IH
H2480
emcdonald on DSK67QTVN1PROD with BILLS
to exceed 5 years. The Director of NIH may ex-
tend the period of support for a center for 1 or 
more additional periods, not to exceed an addi-
tional 5 years, if the operations of such center 
have been reviewed by an appropriate technical 
and scientific peer review group established by 
the Director of NIH and if such group has rec-
ommended to the Director that such period 
should be extended. 
‘‘(c) CEREBRAL CAVERNOUS MALFORMATIONS CON-
SORTIUM.— 
‘‘(1) IN GENERAL.—The Director of NIH shall 
convene a Cerebral Cavernous Malformations Re-
search Consortium (referred to in this section as the 
‘consortium’). 
‘‘(2) MEMBERSHIP.—The consortium— 
‘‘(A) shall include representatives of— 
‘‘(i) the coordinating centers selected 
under subsection (b)(2); and 
‘‘(ii) at least 1 national CCM patient 
advocacy organization, which may be an 
entity that receives a grant or contract 
under subsection (b)(2)(A); and 
‘‘(B) may include representatives of the 
National Institutes of Health or the Food and 
VerDate Sep 11 2014 
02:51 May 28, 2015
Jkt 049200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H2480.IH
H2480
emcdonald on DSK67QTVN1PROD with BILLS
Drug Administration, in an advisory or ex offi-
cio role. 
‘‘(3) RESPONSIBILITIES.—Through a consensus 
based decisionmaking model, the consortium shall 
divide assignments and be responsible for— 
‘‘(A) developing and implementing training 
programs for clinicians and scientists in accord-
ance with paragraph (4); 
‘‘(B) developing patient education, out-
reach, and awareness programs and materials, 
which may be tailored for specific regional 
needs at coordinating centers, including— 
‘‘(i) a regional multimedia public 
awareness campaign; 
‘‘(ii) patient education materials for 
distribution by regional physician and sur-
geon offices; 
‘‘(iii) an education program for ele-
mentary and secondary school nurses to fa-
cilitate early detection and diagnosis of 
CCM in areas in which there is a high den-
sity of cases of CCM; 
‘‘(iv) regular regional patient and 
family-oriented 
educational 
conferences; 
and 
VerDate Sep 11 2014 
02:51 May 28, 2015
Jkt 049200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H2480.IH
H2480
emcdonald on DSK67QTVN1PROD with BILLS
‘‘(v) nationally relevant electronic 
health teaching and communication tools 
and a network of professional capacity and 
patient and family support; and 
‘‘(C) preparing a biannual report to Con-
gress, in accordance with paragraph (5). 
‘‘(4) TRAINING PROGRAM FOR CLINICIANS AND 
SCIENTISTS.— 
‘‘(A) IN
GENERAL.—The consortium, in 
cooperation with the coordinating centers, shall 
establish or expand a physician training pro-
gram, including information and education on 
advances in the diagnosis and treatment of 
CCM, and training and continuing education 
through programs for scientists, physicians, 
medical students, and other health professionals 
and care coordinators who provide care for pa-
tients with CCM, telehealth, and research rel-
evant to CCM, for the purpose of supporting 
the development of new participation centers 
through educational programming to gain the 
expertise needed to become clinical and research 
participation centers with the potential to par-
ticipate in clinical drug trials. 
VerDate Sep 11 2014 
02:51 May 28, 2015
Jkt 049200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6201
E:\BILLS\H2480.IH
H2480
emcdonald on DSK67QTVN1PROD with BILLS
‘‘(B) STIPENDS.—The Director of NIH 
may provide stipends for health professionals 
who are enrolled in the training programs de-
scribed in subparagraph (A). 
‘‘(C) ELIGIBILITY.—To be eligible to par-
ticipate in the training program, an individual 
shall be affiliated with an entity that is in an 
existing clinical research network of the Na-
tional Institutes of Health. 
‘‘(5) REPORT TO CONGRESS.—The consortium 
shall biennially submit to the Committee on Health, 
Education, Labor, and Pensions of the Senate and 
the Committee on Energy and Commerce of the 
House of Representatives a report that describes the 
research, education, and other activities on CCM 
conducted or supported through the Department of 
Health and Human Services. Each such report shall 
include— 
‘‘(A) a research plan; 
‘‘(B) provisions specifying the amounts ex-
pended by the Department of Health and 
Human Services with respect to various forms 
of CCM, including those affected by the com-
mon Hispanic Mutation, Ashkenazi Jewish mu-
tation, CCM3 gene mutations, and other famil-
VerDate Sep 11 2014 
02:51 May 28, 2015
Jkt 049200
PO 00000
Frm 00013
Fmt 6652
Sfmt 6201
E:\BILLS\H2480.IH
H2480
emcdonald on DSK67QTVN1PROD with BILLS
ial and sporadic forms of cerebral cavernous 
malformation; and 
‘‘(C) 
recommendations 
for 
particular 
projects or types of projects that the national 
research institutes or other entities in the field 
of research should conduct on inherited or non- 
inherited forms of CCM.’’. 
SEC. 4. CENTERS FOR DISEASE CONTROL AND PREVEN-
TION CEREBRAL CAVERNOUS MALFORMA-
TIONS SURVEILLANCE AND RESEARCH PRO-
GRAMS. 
Part B of title III of the Public Health Service Act 
(42 U.S.C. 243 et seq.) is amended by inserting after sec-
tion 317T the following: 
‘‘SEC. 317U. CEREBRAL CAVERNOUS MALFORMATIONS SUR-
VEILLANCE AND RESEARCH PROGRAMS. 
‘‘(a) IN GENERAL.—The Secretary, acting through 
the Director of the Centers for Disease Control and Pre-
vention, may award grants in such sums as may be nec-
essary and cooperative agreements to public or nonprofit 
private entities (including State health departments, polit-
ical subdivisions of States, universities, and other medical 
or educational entities) for the collection, analysis, and re-
porting of data on cerebral cavernous malformations (re-
ferred to in this section as ‘CCM’). 
VerDate Sep 11 2014 
02:51 May 28, 2015
Jkt 049200
PO 00000
Frm 00014
Fmt 6652
Sfmt 6201
E:\BILLS\H2480.IH
H2480
emcdonald on DSK67QTVN1PROD with BILLS
‘‘(b) NATIONAL CEREBRAL CAVERNOUS MALFORMA-
TIONS
EPIDEMIOLOGY
PROGRAM.—The Secretary of 
Health and Human Services shall award grants and coop-
erative agreements, including technical assistance, to pub-
lic or nonprofit private entities for— 
‘‘(1) the collection, analysis, and reporting of 
data on CCM; and 
‘‘(2) epidemiological activities, including col-
lecting and analyzing information on the number, in-
cidence, correlates, and symptoms of cases and the 
clinical utility of specific practice patterns. 
‘‘(c) NATIONAL
SURVEILLANCE
PROGRAM.—The 
Secretary shall— 
‘‘(1) provide for a national surveillance program 
for the purpose of carrying out epidemiological ac-
tivities regarding CCM, including collecting and ana-
lyzing information on the number, incidence, cor-
relates, and symptoms of cases of CCM and the clin-
ical utility (including costs and benefits) of specific 
practice patterns; and 
‘‘(2) wherever possible, ensure that the surveil-
lance program is coordinated with the data and sam-
ple collection activities of the National Institutes of 
Health under section 409K. 
VerDate Sep 11 2014 
02:51 May 28, 2015
Jkt 049200
PO 00000
Frm 00015
Fmt 6652
Sfmt 6201
E:\BILLS\H2480.IH
H2480
emcdonald on DSK67QTVN1PROD with BILLS
‘‘(d) TECHNICAL ASSISTANCE.—In making awards 
under this section, the Secretary may provide direct tech-
nical assistance, including personnel support. 
‘‘(e) COORDINATION WITH CLINICAL CENTERS.— 
The Secretary shall ensure that epidemiological informa-
tion is made available to clinical centers as supported by 
the Director of the National Institutes of Health under 
section 409K. 
‘‘(f) AUTHORIZATION OF APPROPRIATIONS.—There 
are authorized to be appropriated such sums as may be 
necessary to carry out this section.’’. 
SEC. 5. FOOD AND DRUG ADMINISTRATION CEREBRAL CAV-
ERNOUS MALFORMATIONS CLINICAL TRIAL 
PREPAREDNESS AND SUPPORT PROGRAM. 
(a) INVESTIGATIONAL NEW DRUG APPLICATION.— 
The Secretary of Health and Human Services, acting 
through the Commissioner of Food and Drugs, shall co-
ordinate with clinical centers, investigators, and advocates 
to support appropriate investigational new drug applica-
tions under section 505(i) of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 355(i)) in an effort to hasten 
the pace of clinical trials for cerebral cavernous malforma-
tion. 
(b) ORPHAN PRODUCT DEVELOPMENT.—Where ap-
plicable in rare subpopulations of cerebral cavernous mal-
VerDate Sep 11 2014 
02:51 May 28, 2015
Jkt 049200
PO 00000
Frm 00016
Fmt 6652
Sfmt 6201
E:\BILLS\H2480.IH
H2480
emcdonald on DSK67QTVN1PROD with BILLS
formation requiring unique pharmacological intervention, 
including subpopulations with the common Hispanic mu-
tation or CCM3 gene mutations, the Commissioner of 
Food and Drugs shall support appropriate requests for 
designations of drugs as orphan drugs under section 526 
of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
360bb). 
Æ 
VerDate Sep 11 2014 
02:51 May 28, 2015
Jkt 049200
PO 00000
Frm 00017
Fmt 6652
Sfmt 6301
E:\BILLS\H2480.IH
H2480
emcdonald on DSK67QTVN1PROD with BILLS